08:29 AM EST, 02/24/2025 (MT Newswires) -- Maravai Lifesciences Holdings ( MRVI ) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.

The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.

Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.